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Abstract An increasing incidence of allergic broncho-
pulmonary aspergillosis (ABPA) as a complication in
patients with cystic ﬁbrosis (CF) is reported. The
objective of this retrospective case-control study was to
assess potential risk factors for ABPA and for Asper-
gillus fumigatus sensitisation (AFS). In a group of 160
CF patients, 11 (7%) fulﬁlled the diagnostic criteria for
ABPA and 20 (13%) had evidence of AFS. They were
compared to 62 control CF patients (25 for ABPA and
37 for AFS group) without evidence of ABPA or AFS
using extended matching for sex, age and weight. AFS
patients had received signiﬁcantly higher cumulative
doses of inhaled corticosteroids than their respective
controls (OR 8.0; 95% CI 1.74–63). Bronchial coloni-
sation with Stenotrophomonas maltophilia was strongly
and independently associated with ABPA (OR 20; 95%
CI 2.8– inﬁnity). A longer duration of Pseudomonas
aeruginosa colonisation was independently associated
with AFS (OR per year 1.50; 95% CI 1.12– inﬁnity).
Conclusion: Cystic ﬁbrosis patients with allergic bron-
chopulmonary aspergillosis have a more frequent
isolation of S. maltophilia in their sputum than
their controls. Longer duration of colonisation with
P. aeruginosa is a risk factor for Aspergillus fumigatus
sensitisation. Higher cumulative doses of inhaled corti-
costeroids are associated with Aspergillus fumigatus
sensitisation and their role as a risk factor needs to be
clariﬁed.
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Introduction
Aspergillus fumigatus is a ubiquitous fungus growing in
humid environments and on decaying organic waste.
Inhalation of spores may result in invasive aspergillosis,
pulmonary aspergilloma, allergic bronchopulmonary
aspergillosis (ABPA), sensitisation to A. fumigatus
(AFS) or asymptomatic colonisation of the bronchial
tree. Predisposing factors such as immunodeﬁciency (e.g.
prolonged severe neutropenia, congenital immunodeﬁ-
ciency syndromes), lung cavities, impaired mucociliary
clearance, asthma and cystic ﬁbrosis (CF) inﬂuence the
clinical course. CF is an autosomal recessive inherited
disease with a defect in the cystic ﬁbrosis transmembrane
regulator (CFTR) gene. The CFTR has a central role in
regulation of salt and water translocation and mutations
in the CFTR gene lead to an altered mucus composition
in aﬀected lungs causing impaired mucociliary clearance.
In patients with CF, an increasing prevalence of ABPA
has been reported and can vary between 0.9% and 13%
[1, 8, 9, 13, 14, 16, 18, 21, 27, 30, 31,35]. In two recent
analyses of epidemiological registries, the reported
prevalence of ABPA was 2.0% in North America among
14210 eligible patients older than 5 years of age [10]
and 7.8% in nine European countries among 12447
patients [19].
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Clinical presentation, ﬁndings on chest X-ray ﬁlms or
CT scans and laboratory data are combined for the
diagnosis of ABPA and AFS. There have been many
proposals for a set of diagnostic criteria for ABPA with
marked nonconformity between diﬀerent authors [1, 10,
14, 16, 18, 19, 21,26]. Therefore a consensus conference
held in 2001, proposed the following diagnostic criteria
for ABPA [33]: (1) clinical deterioration (cough, wheeze,
exercise intolerance, exercise-induced asthma, decline in
pulmonary function, increased sputum), (2) serum total
IgE concentration of >1000 IU/ml, (3) immediate
cutaneous reactivity to A. fumigatus in prick skin test or
in vitro presence of serum IgE antibody to A. fumigatus,
(4) precipitating antibodies to A. fumigatus or serum
IgG antibody to A. fumigatus by an in vitro test, and (5)
new or recent abnormalities on chest radiography or
chest CT that have not cleared with antibiotics and
standard physiotherapy.
In patients with CF, the clinical, imaging and labo-
ratory criteria are constantly inﬂuenced by the disease
itself and the underlying lung pathology, therefore the
criteria are diﬃcult to apply. Fluctuations in clinical
presentation due to viral or bacterial pulmonary
infections further limit the accurate diagnosis [8,30].
Recently, the IgE response towards recombinant A.
fumigatus allergens (rAsp f) has been proposed to im-
prove diagnosis of allergic diseases related to A. fumig-
atus in CF patients. Serological investigations involving
a panel of recombinant allergens (Asp f1, Asp f3, Asp f4,
Asp f6) show a high sensitivity and speciﬁcity in the
detection of ABPA and AFS [5,12]. The distinction
between ABPA and AFS is crucial to determine ther-
apy. In the case of ABPA, therapy consists of oral
corticosteroids and a systemic antifungal agent (i.e. itr-
aconazole), and some groups recommend inhaled
corticosteroids [19, 21,22]. Speciﬁc recommendations for
treating patients with AFS do not exist.
The presence of atopy, the use of inhaled antibiotics,
decreased forced expiratory volume (FEV 1) and Pseu-
domonas aeruginosa in sputum have been suggested as
risk factors for the development of ABPA in patients
with CF [3, 10, 22].
The impact on CF is not yet clear, but ABPA is
suspected to cause a more rapid decline in pulmonary
function and a more rapid progression of CF lung
disease [8, 24,34]. Early recognition or even prevention is
important and knowledge of risk factors will change the
management of CF patients. To evaluate putative risk
factors for CF patients to acquire either ABPA or AFS,
we performed a case-control study on the basis of our
CF registry.
Subjects and methods
Subjects
The CF registry of the Department of Paediatrics at the
University of Berne contains data of CF patients fol-
lowed at our clinic and was started in 1994. After
written informed consent of the patients or their next of
kin is obtained, patient’s data are entered continuously
into the registry. All patients entering the database
have a diagnosis of CF conﬁrmed by a positive sweat
test with increased sweat chloride concentration
(>60 mmol/l) and DNA analysis of a CF speciﬁc
genotype. The patients are seen regularly depending on
their clinical course but at least once a year. All clinical,
anthropometric, radiological and laboratory data are
available from the time of initial diagnosis. The col-
lection of these data was approved by the ethics com-
mittee of the Medical Faculty of the University of
Berne.
Selection of cases
In December 2000, the CF database was searched to
identify patients with ABPA or AFS fulﬁlling all of the
following criteria.
Patients with ABPA: (1) clinical signs, i.e. more
coughing, wheezing, increasing expectorations; (2) in-
creased (‡ 2SD of normal ) total serum IgE concen-
tration based on normal age corrected values
(ImmunoCAP-FEIA-System); age 3–4 years >20 IU/
ml; 4–7 years >160 IU/ml; 10–14 years >570 IU/ml;
older than 14 years >195 IU/ml); (3) positive speciﬁc
IgE in serum against A. fumigatus with RAST class ‡2
(Pharmacia; corresponding to >3.5 kU/l); (4) in-
creased speciﬁc IgG in serum against A. fumigatus
>20 kU/l (reference values in [12]); (5) increased
speciﬁc IgE in serum against rAsp f1 >9.6 EU/ml and
rAsp f4 >8.4 EU/ml and rAsp f6 >7.2 EU/ml (ref-
erence values in [12]) and (6) at least one positive
culture result from sputum or pharyngeal swab for
A. fumigatus.
Patients with AFS: (1) positive speciﬁc IgE in serum
against A. fumigatus (RAST class ‡2) and/or increased
speciﬁc IgE in serum against rAsp f1 >9.6 EU/ml, with
normal values for rAsp f4 ( £ 8.4 EU/ml) and rAsp f6
( £ 7.2 EU/ml) and (2) the remaining above mentioned
criteria for ABPA not fulﬁlled.
Selection of controls
For each patient of the ABPA and AFS groups, the CF
registry was searched for at least one matched control
patient. More than one control was taken per case when
available (extended matching) in order to enhance the
power of comparison [2, 20,32]. The following matching
criteria were used: (1) same sex as the case patient, (2)
age ±18 months to the case patient, (3) weight ±5 kg
and height ±20 cm compared to the case patient, (4)
negative sputum and/or pharyngeal swab culture for A.
fumigatus, (5) total serum IgE as well as IgE RAST
against A. fumigatus in the normal (age corrected) range
and (6) normal serum values for speciﬁc IgG against
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A. fumigatus and speciﬁc IgE against rAsp f1, rAsp f4
and rAsp f6.
Variables
Data of patients who were seen at least twice a year
during outpatient follow-up were analysed. The follow-
ing variables, which were obtained from the database
and before 1994 from medical records, were included in
this case-control study: (1) CF genotype; (2) dose,
duration and substance of prescribed inhaled corticos-
teroids; (3) chronic colonisation with P. aeruginosa, i.e.
positive microbiological assays of the sputum or throat
swab at least twice a year; (4) presence of S. maltophilia
in sputum or throat swab.
Body mass index (BMI) was calculated as weight/
height2 (kg/m2) and standard deviation score (z-score)
was calculated relative to a Swiss reference population
[29].
Statistical analysis
Because of the small sample sizes, exact methods were
used throughout. Risk factors for ABPA or AFS were
analysed with univariate and multivariate stratiﬁed lo-
gistic regression (exact conditional type, with the mat-
ched-set identiﬁer as stratiﬁcation variable). This kind of
analysis is adapted to the case-control data with ex-
tended matching. Exact 95% CI were calculated for OR
and proportions [4]. LogXact-4.1 and StatXact-5.0.3
software was used (Cytel Software, Cambridge, USA).
Results
Of 160 patients in the CF registry, 11 (7%; 95% CI 4%–
12%), fulﬁlled the criteria for ABPA and 20 (12%; 95%
CI 8%–19%) for AFS. A total of 25 CF controls (1 to 5
per case) were matched to the ABPA group and 37 (1 to
5 per case) to the AFS group. Table 1 gives information
on gender, age, weight and height of cases and controls.
The proportions of CFTR mutations in the diﬀerent
groups were comparable (Table 2).
The associations of speciﬁc variables with the pres-
ence of ABPA and AFS given in Table 3 and Table 4
respectively. Before a diagnosis of AFS was made, the
median cumulative dose of inhaled steroids in AFS cases
was signiﬁcantly higher than in their controls (0.57 g;
interquartile range (IQR) 0.27–0.86 g vs. 0.00 g; IQR
0.00–0.43 g; P =0.004). Multivariate analysis showed
that this association was independent of other factors.
The median cumulative dose of inhaled steroids in
ABPA cases, however, was not signiﬁcantly higher
compared to their controls (0.81 g; IQR 0.46–1.34 g vs.
0.52 g; IQR, 0.00–1.02 g; P =0.055). The median
duration of P. aeruginosa colonisation was comparable
in ABPA patients and their controls (5 years; IQR 2–10
years vs. 6 years; IQR 2–9 years; P =1.00), but signiﬁ-
cantly higher in AFS cases than in their controls
(7 years; IQR 5–8 years vs. 2 years; IQR 1–4 years; P
<0.001), corresponding to a per-year OR of 2.0 (95%
CI 1.3–3.9). Multivariate analysis showed that this as-
sociation was again independent of other factors.
S. maltophilia was isolated in sputum or throat swab
at least once in a signiﬁcantly higher proportion of
ABPA patients than in their controls (9 of 11=82%;
95% CI 50%–97% vs. 1 of 25=4%; 95% CI 0.2%–
19%; P <0.001) and its presence was independently
associated with ABPA. AFS patients did not diﬀer sig-
niﬁcantly from their controls in that variable (2 of
20=10%; 95% CI 2%–32% vs. 3 of 37=8%; 95% CI
2%–21%; P =1.00).
Discussion
This is the ﬁrst case-control study of CF patients which
analyses risk factors for ABPA and AFS. The preva-
Table 1 Sex, age, weight, height, BMI and z-scores in the diﬀerent
groups
ABPA
(n=11)
ABPA
controls
(n=25)
AFS
(n=20)
AFS
controls
(n=37)
Female 6 12 8 13
Male 5 13 12 24
Median age (years) 12 14 12 9
Median weight (kg) 27 36 28 28
Median height (m) 1.35 1.49 1.34 1.34
Median BMI 15.8 13.9 15.6 16.6
Median BMI
z-score
-0.90* -1.28 -0.53 -0.15
* P =0.007 signiﬁcantly diﬀerent from ABPA controls; all other
diﬀerences were not signiﬁcant
Table 2 Distribution of CFTR gene mutations in cases with
ABPA, AFS and their control groups. (Pearsons v2 = 9.3, exact
P =0.41)
CFTR
mutation
ABPA
(n=2·11)
ABPA
controls
(n=2·25)
AFS
(n=2·20)
AFS
controls
(n=2·37)
DF508 18 (82%) 41 (82%) 31 (78%) 49 (66%)
3905insT 0 (0%) 1 (2%) 4 (10%) 7 (9%)
R553X 1 (5%) 2 (4%) 1 (3%) 7 (9%)
Others 3 (14%) 6 (12%) 4 (10%) 11 (15%)
1717–1G+
17 1199DelG
R347P 2176insC G126D
R560S 2347delG G542X G542X
Q523X Q525X E585X
3732delA N1303K 4005+1G->A
M1101K
K710X
Q525X
3732delA
N1303K
2789+5G->A
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lence of ABPA in our centre is 7%, compared to 0.9%
for Denmark [30], 2.0% for North America [10], 10%
for Canada [9] and 13.6% for Belgium [19]. The reported
variation of ABPA prevalence in CF patients is rather a
consequence based on diﬃculties in diagnosis using
diﬀerent criteria than due to epidemiological diﬀerences.
The diagnosis of ABPA in our study was based on the
criteria of the Cystic Fibrosis Foundation consensus
conference [33] with the following specifying modiﬁca-
tions: increased IgE was deﬁned for age corrected
normal values, imaging was not taken into account and
A. fumigatus was cultured at least once in the sputum.
Additionally, speciﬁc IgE against rAsp f were used. The
development of antibodies to recombinant allergens has
recently been reported [5, 12,15] and shows an
improvement in diagnosis as well as the capacity to
distinguish between ABPA patients (even during remis-
sion) and AFS patients.
The prevalence of AFS in our centre is 13%. Usually
skin prick tests and/or speciﬁc IgE (RAST) against A.
fumigatus are used for this diagnosis. Using either po-
sitive skin test or elevated speciﬁc IgE titre (RAST >2),
Wojnarowski et al. [34] found 26% AFS patients in their
clinic in Vienna and Nikolaizik et al. [25,26] described
105 CF patients in the UK of whom 30% had positive
skin tests to A. fumigatus and 23% had positive IgE
antibody to A. fumigatus. The reliability of skin tests is
limited as they depend on the composition of antigen
preparation [12,26] and therefore skin tests are not
routinely done, as was the case in our patients. Instead
of skin testing we used a combination of speciﬁc IgE
(RAST) against A. fumigatus and speciﬁc IgE against
recombinant allergens (rAsp f) to deﬁne AFS [12]. Due
to these more speciﬁc criteria, our rate of AFS patients is
lower than in other cohorts.
AFS was signiﬁcantly and independently (from other
factors) associated with higher doses of inhaled corticos-
teroids. Postulating inhaled corticosteroids as a risk fac-
tor, a possible pathway for sensitisation might be a
depressed immune function by steroids (especially mac-
rophages ingesting and killing spores), leading to en-
hanced germination ofA. fumigatus and increased release
of allergens. Moreover, in vitro pharmacological doses of
hydrocortisone increase the growth rate of A. fumigatus
via a possible presence of a ligand/receptor system [28].
An association of inhaled corticosteroids with AFS has
not been previously found and the increasing use of in-
haled corticosteroids for inﬂammation control in CF
patients is therefore of major concern [23].
Whether sensitisation is a preliminary state for pa-
tients who develop ABPA later has never been shown
and few data are available showing whether ABPA pa-
tients are able to return to AFS (Fig. 1). Hutcheson and
coworkers [13], in their longitudinal study of ABPA and
AFS patients, showed that reactivity of the skin prick
test, speciﬁc IgE and IgG against A. fumigatus as well as
increased total IgE were sometimes lost spontaneously.
Because we concentrated in our study on the time before
diagnosis, we are not able to answer conclusively the
question as to what happens with ABPA patients after
treatment. We followed up our ABPA patients (data not
shown) with determinations of antibodies to re-
combinant allergens and we occasionally saw that they
can return to an AFS state.
The duration of colonisation with P. aeruginosa in
ABPA patients was similar to their controls. These
ﬁndings correspond to those of Simmonds et al. [31] who
reported that only 3 of their 11 ABPA patients had
chronic P. aeruginosa colonisation; on the other hand,
this was not seen in a survey of 16 ABPA patients in the
United States [22].
In AFS patients, however, a signiﬁcantly longer
colonisation of P. aeruginosa was seen. An association
between P. aeruginosa and positive skin test as well as
positive speciﬁc IgE against A. fumigatus in serum
has been shown previously [25]. In vitro it seems that
P. aeruginosa can alter growth and phenotype of
Table 3 Cases with ABPA versus controls
Univariate exact
logistic regression
OR (exact 95% CI) P
Inhaled steroids
(cumulative dose in g)
4.8 (0.97–38) Not
signiﬁcant
Years of P. aeruginosa
colonisation
1.0 (0.88–1.13) Not
signiﬁcant
Ever colonised with
S. maltophilia
20 (2.8– inﬁnity) <0.001
BMI z-score 0.13 (0.02–0.7) 0.007
Multivariate exact
logistic regression
OR (exact 95% CI) P
Ever colonised with
S. maltophilia
20.1 (2.8– inﬁnity) <0.001
All the other variables Not
signiﬁcant
Table 4 Cases with AFS versus controls
Univariate exact
logistic regression
OR (exact 95% CI) P
Inhaled steroids
(cumulative dose in g)
8.0 (1.7–63) 0.004
Years of P. aeruginosa
colonisation
2.0 (1.3–3.9) <0.001
Ever colonised with
S. maltophilia
1.2 (0.1–17) Not
signiﬁcant
BMI z-score 0.58 (0.2–1.3) Not
signiﬁcant
Multivariate exact
logistic regression
OR (exact 95% CI) P
Inhaled steroids
(cumulative dose in g)
26.6 (2.1–3588) 0.007
Years of P. aeruginosa
colonisation
1.50 (1.12– inﬁnity) 0.001
All the other variables Not signiﬁcant
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A. fumigatus [22], increase the release of protein structures
of the fungus and hence cause sensitisation [34]. Of course
we are unable to distinguish between association and
cause, but it seems plausible that a longer P. aeruginosa
presence in the bronchial tree is a risk factor for AFS.
Of 11 ABPA patients, 9 harboured S. maltophilia at
least once, whereas in all the other groups this was a rare
observation. The association between the isolation of
A. fumigatus and subsequent S. maltophilia infection has
been shown recently [17]. The study design of this group
made no distinction between AFS, ABPA and non-AFS/
nonABPA groups. Our data suggest that the association
is true for the ABPA but not for the sensitised group.
The reason for the susceptibility in CF patients might be
a more advanced lung disease, but both lung function
before and after acquisition of S. maltophila have been
studied and no signiﬁcant deterioration was reported
[6,17]. In our study we refrained from the analysis of
lung function, as there were too many missing values due
to children under 6 years of age and the number of lung
function tests that were done varied much depending on
patients clinical state.
The signiﬁcance of S. maltophilia in ABPA patients
remains unclear, but it is possibly a marker for a dif-
ferent response to microorganisms, without or before
changes in lung function occur. In our study, the pres-
ence of S. maltophilia in ABPA patients was independent
of the use of inhaled corticosteroids. Two previous
studies looked at the inﬂuence of systemic and/or in-
haled corticosteroids on S. maltophilia isolation and
both failed to show an association [11,17].
The question whether CFTR gene mutations play a
role in the aetiology of ABPA has been raised by the
ﬁnding that atopic asthmatics showed a higher than
expected prevalence of carriers with CFTR mutations
[7]. We did not ﬁnd an association of type of CFTR gene
mutation with ABPA or AFS.
By choosing a matched case-control design, we were
not able to evaluate if sex or age are risk factors. The
fact that mean age was diﬀerent in cases compared to
controls was due to extended matching, where more
than one control was selected per case. The mode of
analysis, i.e. stratiﬁed logistic regression, avoided an
inﬂuence of this diﬀerence on the results. In the uni-
variate analysis of BMI z-scores we realised that the
groups diﬀered more from each other than expected
after being matched. Multivariate analysis corrected this
problem, demonstrating that a lower BMI was not
independently associated with ABPA.
The use of extended instead of the usual one-to-one
matching was chosen to increase statistical power. Fur-
thermore, exact nonparametric statistical methods were
applied because of small sample sizes and non-normal
distributed variables. The application of the exact type of
analysis will not yield incorrect results even in small
samples, thus allowing multivariate analyses even with
Fig. 1 Hypothesis for the
pathogenesis of colonisation,
AFS and of ABPA
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few patients [2, 20,32]. Both the study type and the cor-
responding type of analysis are scientiﬁcally well-foun-
ded but not widely known methods to ﬁnd associations
between a disease entity with only a few patients and a
number of risk factors. Of course, the problem of gen-
eralisation of results observed in small patient samples
remains and cautious interpretation is implicated. Large
prospective studies are needed to further understand and
evaluate the diﬀerences between ABPA, AFS and CF
patients with no allergic reaction to A. fumigatus.
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